| 000 | 01666 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250513051200.0 | ||
| 264 | 0 | _c19940131 | |
| 008 | 199401s 0 0 eng d | ||
| 022 | _a0041-1132 | ||
| 024 | 7 |
_a10.1046/j.1537-2995.1994.34194098603.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSloand, E | |
| 245 | 0 | 0 |
_aTransfusion of blood components to persons infected with human immunodeficiency virus type 1: relationship to opportunistic infection. _h[electronic resource] |
| 260 |
_bTransfusion _cJan 1994 |
||
| 300 |
_a48-53 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAIDS-Related Opportunistic Infections _xblood |
| 650 | 0 | 4 |
_aBlood Component Transfusion _xadverse effects |
| 650 | 0 | 4 |
_aBlood Group Antigens _ximmunology |
| 650 | 0 | 4 | _aCD4-CD8 Ratio |
| 650 | 0 | 4 |
_aCD4-Positive T-Lymphocytes _xcytology |
| 650 | 0 | 4 | _aCell Count |
| 650 | 0 | 4 |
_aCytomegalovirus Infections _xtransmission |
| 650 | 0 | 4 |
_aDidanosine _xtherapeutic use |
| 650 | 0 | 4 |
_aErythrocyte Transfusion _xadverse effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHIV-1 |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIsoantibodies _xblood |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMycobacterium avium-intracellulare Infection _xtransmission |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aZalcitabine _xtherapeutic use |
| 650 | 0 | 4 |
_aZidovudine _xtherapeutic use |
| 700 | 1 | _aKumar, P | |
| 700 | 1 | _aKlein, H G | |
| 700 | 1 | _aMerritt, S | |
| 700 | 1 | _aSacher, R | |
| 773 | 0 |
_tTransfusion _gvol. 34 _gno. 1 _gp. 48-53 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1046/j.1537-2995.1994.34194098603.x _zAvailable from publisher's website |
| 999 |
_c7903162 _d7903162 |
||